1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Anti VEGF Drugs
        1.2.3 Photosensitive Drugs
        1.2.4 Others
    1.3 Market by Application
        1.3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Exudative ARMD
        1.3.3 Atrophy ARMD
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2017-2028)
    2.2 Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Region
        2.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Region (2017-2022)
        2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2023-2028)
    2.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Dynamics
        2.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Trends
        2.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
        2.3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
        2.3.4 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue
        3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2017-2022)
        3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2017-2022)
    3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
    3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
        3.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2021
    3.5 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
    3.6 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
    3.7 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Type
    4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2017-2022)
    4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2023-2028)
5 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Application
    5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Application (2017-2022)
    5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
    6.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        6.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
        6.2.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
        6.2.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
    6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        6.3.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
        6.3.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
        6.3.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
    6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
        6.4.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
        6.4.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
    7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        7.2.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
        7.2.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
        7.2.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
    7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        7.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
        7.3.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
        7.3.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
    7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
        7.4.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
        7.4.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
    8.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        8.2.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
    8.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        8.3.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
    8.4 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region
        8.4.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
    9.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        9.2.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
        9.2.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
        9.2.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
    9.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        9.3.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
        9.3.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
        9.3.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
    9.4 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
        9.4.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
        9.4.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2017-2028)
    10.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        10.2.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2017-2028)
    10.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        10.3.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2017-2028)
    10.4 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
        10.4.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.1.5 Roche Recent Developments
    11.2 Regeneron Pharmaceuticals
        11.2.1 Regeneron Pharmaceuticals Company Details
        11.2.2 Regeneron Pharmaceuticals Business Overview
        11.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.2.5 Regeneron Pharmaceuticals Recent Developments
    11.3 Bayer
        11.3.1 Bayer Company Details
        11.3.2 Bayer Business Overview
        11.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.3.5 Bayer Recent Developments
    11.4 Santen Oy
        11.4.1 Santen Oy Company Details
        11.4.2 Santen Oy Business Overview
        11.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.4.5 Santen Oy Recent Developments
    11.5 Kanghong Pharmaceuticals
        11.5.1 Kanghong Pharmaceuticals Company Details
        11.5.2 Kanghong Pharmaceuticals Business Overview
        11.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.5.5 Kanghong Pharmaceuticals Recent Developments
    11.6 Novartis
        11.6.1 Novartis Company Details
        11.6.2 Novartis Business Overview
        11.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.6.5 Novartis Recent Developments
    11.7 Eli Lilly and Company
        11.7.1 Eli Lilly and Company Company Details
        11.7.2 Eli Lilly and Company Business Overview
        11.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.7.5 Eli Lilly and Company Recent Developments
    11.8 TRACON Pharmaceuticals
        11.8.1 TRACON Pharmaceuticals Company Details
        11.8.2 TRACON Pharmaceuticals Business Overview
        11.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.8.5 TRACON Pharmaceuticals Recent Developments
    11.9 Pfizer
        11.9.1 Pfizer Company Details
        11.9.2 Pfizer Business Overview
        11.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.9.5 Pfizer Recent Developments
    11.10 GSK
        11.10.1 GSK Company Details
        11.10.2 GSK Business Overview
        11.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.10.5 GSK Recent Developments
    11.11 BIOCAD
        11.11.1 BIOCAD Company Details
        11.11.2 BIOCAD Business Overview
        11.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
        11.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
        11.11.5 BIOCAD Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Anti VEGF Drugs
    Table 3. Key Players of Photosensitive Drugs
    Table 4. Key Players of Others
    Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2017-2022)
    Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2023-2028)
    Table 11. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends
    Table 12. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
    Table 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
    Table 14. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
    Table 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players (2017-2022)
    Table 17. Global Top Age-relatedMacularDegeneration (ARMD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2021)
    Table 18. Ranking of Global Top Age-relatedMacularDegeneration (ARMD) Drugs Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
    Table 22. Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2017-2022)
    Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2023-2028)
    Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2017-2022)
    Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2023-2028)
    Table 32. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Roche Company Details
    Table 63. Roche Business Overview
    Table 64. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 65. Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 66. Roche Recent Developments
    Table 67. Regeneron Pharmaceuticals Company Details
    Table 68. Regeneron Pharmaceuticals Business Overview
    Table 69. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 70. Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 71. Regeneron Pharmaceuticals Recent Developments
    Table 72. Bayer Company Details
    Table 73. Bayer Business Overview
    Table 74. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 75. Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 76. Bayer Recent Developments
    Table 77. Santen Oy Company Details
    Table 78. Santen Oy Business Overview
    Table 79. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 80. Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 81. Santen Oy Recent Developments
    Table 82. Kanghong Pharmaceuticals Company Details
    Table 83. Kanghong Pharmaceuticals Business Overview
    Table 84. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 85. Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 86. Kanghong Pharmaceuticals Recent Developments
    Table 87. Novartis Company Details
    Table 88. Novartis Business Overview
    Table 89. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 90. Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 91. Novartis Recent Developments
    Table 92. Eli Lilly and Company Company Details
    Table 93. Eli Lilly and Company Business Overview
    Table 94. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 95. Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 96. Eli Lilly and Company Recent Developments
    Table 97. TRACON Pharmaceuticals Company Details
    Table 98. TRACON Pharmaceuticals Business Overview
    Table 99. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 100. TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 101. TRACON Pharmaceuticals Recent Developments
    Table 102. Pfizer Company Details
    Table 103. Pfizer Business Overview
    Table 104. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 105. Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 106. Pfizer Recent Developments
    Table 107. GSK Company Details
    Table 108. GSK Business Overview
    Table 109. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 110. GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 111. GSK Recent Developments
    Table 112. BIOCAD Company Details
    Table 113. BIOCAD Business Overview
    Table 114. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product
    Table 115. BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022) & (US$ Million)
    Table 116. BIOCAD Recent Developments
    Table 117. Research Programs/Design for This Report
    Table 118. Key Data Information from Secondary Sources
    Table 119. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type: 2021 VS 2028
    Figure 2. Anti VEGF Drugs Features
    Figure 3. Photosensitive Drugs Features
    Figure 4. Others Features
    Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2021 VS 2028
    Figure 6. Exudative ARMD Case Studies
    Figure 7. Atrophy ARMD Case Studies
    Figure 8. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
    Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region: 2021 VS 2028
    Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players in 2021
    Figure 13. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2021
    Figure 15. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 16. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
    Figure 17. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
    Figure 18. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
    Figure 19. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
    Figure 23. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
    Figure 24. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
    Figure 25. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 32. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
    Figure 33. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
    Figure 34. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Region (2017-2028)
    Figure 35. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 41. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 42. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
    Figure 43. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
    Figure 44. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
    Figure 45. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 48. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2028)
    Figure 49. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2028)
    Figure 50. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Country (2017-2028)
    Figure 51. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Roche Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 55. Regeneron Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 56. Bayer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 57. Santen Oy Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 58. Kanghong Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 59. Novartis Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 60. Eli Lilly and Company Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 61. TRACON Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 62. Pfizer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 63. GSK Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 64. BIOCAD Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed